Expanded Access Study Assessing Efficacy and Safety of Nivolumab in Italian Patients with Stage IIIB/Stage IV Non-Small-Cell-Lung-Cancer: A Real World Experience

Trial Profile

Expanded Access Study Assessing Efficacy and Safety of Nivolumab in Italian Patients with Stage IIIB/Stage IV Non-Small-Cell-Lung-Cancer: A Real World Experience

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Preliminary results (as of Mar 2017) assessing efficacy and safety of nivolumab monotherapy in patients with non-squamous non-small cell lung cancer (NSCLC), presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results (n=409) assessing efficacy and safety of nivolumab in patients with advanced non-squamous NSCLC and brain metastases, presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Preliminary results assessing efficacy of nivolumab in never smokers and EGFR positive patients, presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top